Business Wire

NY-PHILIP-MORRIS-INTL

19.1.2021 10:54:46 CET | Business Wire | Press release

Share
PMI’s Charles Bendotti Recognized by INvolve and Yahoo Finance on OUTstanding 50 Ally Executives List 2020; Nikki Symmons named on LGBT+ Future Leader List 2020

Charles Bendotti, Senior Vice President, People & Culture at Philip Morris International Inc. (PMI) (NYSE:PM), has today been recognized for his unwavering support for LGBTQ+ inclusion in the workplace, included on INvolve and Yahoo Finance’s OUTstanding 50 Ally Executives List 2020. The designation places Bendotti among a select group of business leaders and allies of LGBTQ+ inclusion recognized for driving cultural change within the workplace to create more inclusive environments across the world. Nikki Symmons, Content Planner, Global Communications at PMI, has also been named on the OUTstanding LGBT+ Future Leader List 2020 in recognition of her achievements in furthering LGBTQ+ inclusion both within PMI and beyond.

“I’ve been fortunate to have lived and led in many countries throughout my career, working with people from a variety of backgrounds and cultures who have taught me the value of inclusion and diversity first-hand,” said Bendotti. “I’m honored to be recognized as a global ally and included on the OUTstanding 50 Ally Executives List this year. As leaders it’s critical that everyone—without exception—feels valued, respected, and empowered to succeed.”

Bendotti’s recognition stems from his efforts in championing inclusion and diversity (I&D) within PMI and beyond. He was instrumental in championing the appointment of the company’s first Chief Diversity Officer, Silke Muenster, in March 2020; a role that reports directly to the CEO. Additionally, he is actively involved in advancing LGBTQ+ inclusion within the organization as executive sponsor of PMI’s global employee resource group, STRIPES, which aims to create a safe space for learning, sharing, allyship, and support to members and allies of the LGBTQ+ community.

Suki Sandhu OBE, founder, and CEO of INvolve, the consultancy and global network championing diversity and inclusion in business, said: “I’m thrilled to be celebrating another amazing group of LGBT+ and Ally role models from across the globe who are championing inclusion and inspiring the next generation of talent. LGBT+ discrimination is still prevalent across the world, and role models are essential to change perceptions and show everyone that you can be successful in business while also being your authentic self at work.”

For inclusion on the OUTstanding 50 Ally Executives List 2020, nominees’ seniority and influence were taken into consideration and their impact on LGBTQ+ inclusion inside and outside the workplace, as well as business achievements. They must be a vocal ally, actively working to create an environment where LGBTQ+ people can comfortably bring their best professional selves to work.

OUTstanding’s judging panel consisted of Lord Browne, executive chairman, L1 Energy; Ashok Vaswani, global consumer and payments head, Barclays; Harriet Green, former chairman and CEO, IBM Asia Pacific; Dawn Airey, independent director, Grosvenor Estates GBI; Jim Fitterling, CEO of Dow Inc.; Suki Sandhu OBE, founder and CEO, INvolve and Audeliss; and Lianna Brinded, head of Yahoo Finance UK.

The full list of nominees can be viewed here . For more information on PMI’s I&D efforts, click here .

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

About INvolve and OUTstanding

OUTstanding is part of INvolve, the consultancy and global network championing diversity and inclusion in business. Through the delivery of events, programs, thought leadership, and advisory services, INvolve helps firms drive cultural change and create inclusive workplaces where any individual can succeed. INvolve also publishes EMpower, HERoes, and OUTstanding role model lists annually, recognizing and celebrating business leaders and future leaders who are breaking down barriers at work and inspiring the next generation of diverse talent. For more information, please visit www.involvepeople.org

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye